RSV Therapeutics LLC
Quick facts
Phase 3 pipeline
- XC221 · Infectious Disease
XC221 is a small molecule that inhibits the activity of the SARS-CoV-2 main protease.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: